Top Markets
#1 Islamic Coin Islamic Coin +151.30%
#2 Akedo Akedo +77.68%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.65%
#5 Cross Cross +44.14%
#6 Black Phoenix Black Phoenix +33.98%
#7 Velvet Velvet +25.65%
#8 Cap Cap +25.20%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.99%
#10 Palladium Network Palladium Network +12.46%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
OncoCyte Corporation OncoCyte Corporation

OncoCyte Corporation

OCX
Kedudukan dalam Saham #38932
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Harga Saham
$2.84
Disegerakkan terakhir: 2025-07-14
Modal Pasaran
$729.71K
Perubahan (1 hari)
-0.70%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan OncoCyte Corporation (OCX)

Kategori

Healthcare
Pendapatan untuk OncoCyte Corporation (OCX)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini OncoCyte Corporation, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi OncoCyte Corporation dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE